ABSTRACT
Objective: To evaluate the effect of N-benzyl-4-bromobenzamide [NBBA] on lipopolysaccharide [LPS]-induced IL-6 and prostaglandin E[2] [PGE[2]] production in human gingival fibroblasts [HGFs]
Material and Methods:The benzamide compound was synthesized. The condition for IL-6 production of HGFs after induction with LPS was optimized. The HGFs were incubated with NBBA [10 micro g/ml] for 30 min before LPS [1 micro g/ ml] was added. After 24 h of incubation time, the culture media were harvested and their IL-6 and PGE[2] contents were determined using an enzyme-linked immunosorbent assay. Prednisolone [PDS] and NS-398 were used as positive controls. Statistical analysis of the IL-6 and PGE[2] contents was performed using the ANOVA test followed by the Tukey multiple- comparisons test to compare replicate means. p < 0.001 was considered statistically significant
Results:The maximum IL-6 production was achieved when HGFs were exposed to 1 micro g/ml of LPS for 24 h, which was inhibited by the IL-6 immunosuppressant PDS. The benzamide compound, NBBA, exhibited a potent anti-IL-6 activity with inhi- bition of 35.6 +/- 0.5%, significantly different from in the LPSinduced HGFs [p < 0.001]. In addition, it inhibited 75.6 +/- 0.52% PGE[2] production. Cell viability was not significantly affected by treatment with NBBA at a concentration <10 micro g/ ml [p < 0.001]
Conclusions:NBBA exhibited an inhibitory effect on the production of IL-6 and PGE[2] in LPS-induced HGFs. It could serve as a compound with inhibiting inflammatory activity in periodontal disease